Finding new lanes: Chimeric antigen receptor (CAR) T-cells for myeloid leukemia.

ABSTRACT:

Background

Myeloid leukemia represents a heterogeneous group of cancers of blood and bone marrow which arise from clonal expansion of hematopoietic myeloid lineage cells. Acute myeloid leukemia (AML) has traditionally been treated with multi-agent chemotherapy, but conventional therapies have not improved the long-term survival for decades. Chronic myeloid leukemia (CML) is an indolent disease which requires lifelong treatment, is associated with significant side effects, and carries a risk of progression to potentially lethal blast crises.

Recent findings

Recent advances in molecular biology, virology, and immunology have enabled researchers to grow and modify T lymphocytes ex-vivo. Chimeric antigen receptor (CAR) T-cell therapy has been shown to specifically target cells o

SUBMITTER: Pratap S 

PROVIDER: S-EPMC7941581 | biostudies-literature | 2020 Apr

REPOSITORIES: biostudies-literature